Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (“MS”). Following U.S. Food and Drug
Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements.
Hydrofarm (NASDAQ: HYFM) announced the closing of its previously disclosed registered direct offering of 1,599,400 common shares at $0.905 per share and concurrent private placement of 7,611,575 unregistered common shares or pre-funded warrants and 9,210,975 common stock purchase warrants. The
According to a recent analysis conducted by Ember, national energy storage targets for 2030 collectively fall 45% short of the 1,500-gigawatt global target agreed at COP29, despite rapid growth in actual installations.
Energy Ministers from Canada and Turkey have signed a deal that enters both countries into a strategic bilateral partnership focused on renewable energy, nuclear energy, and liquefied natural gas (LNG). Canada’s Minister of Energy & Natural Resources Timothy Hodgson met
Israeli Prime Minister B. Netanyahu has proposed crypto as a possible way for the country to maintain financial channels if international sanctions increasingly restrict its access to the global banking system.
Europe’s car industry is at a very important point. For many years, gasoline and diesel cars have been a big part of life in Europe. They have supported factories, jobs, and travel. But now, electric cars, high fuel prices, climate
SS Innovations (NASDAQ: SSII), a developer of innovative surgical robotic technologies, showcased its surgical robotics platform in a series of remote operations during October medical conferences in Spain and India, including a robotic-assisted cardiac procedure performed by a surgeon approximately
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
This article has been disseminated on behalf of Shelfie-Tech Ltd. and may include paid advertising.
Nightfood Holdings (OTCQB: NGTF) is featured in a NetworkNewsAudio Audio Press Release (“APR”) titled “Inspection, Automation Equipment Could Be Overlooked Winners of the AI Buildout.” The audio release examines growing demand for advanced semiconductor inspection and automation equipment as artificial
Silynxcom (NYSE American: SYNX), a developer of advanced soldier-worn tactical communication solutions, is developing an artificial intelligence-powered wearable drone-detection system designed to warn soldiers of approaching unmanned aircraft, marking a strategic move by the tactical communications company into the counter-drone
FingerMotion (NASDAQ: FNGR) announced that it has entered into a non-binding term sheet with BlueFlare Group Holdings Inc., a Calgary-based developer of behind-the-meter power generation and modular high-performance computing infrastructure, regarding a potential business combination. The proposed transaction would create
American Fusion (OTC: AMFN) is advancing testing of its Texatron(TM) Fusion Engine(TM) as it explores opportunities to supply electricity to AI data centers and other power-intensive customers. In a recent AGORACOM interview, Executive Chairman Brent Nelson discussed the company’s 500-kW
Versus Systems (NASDAQ: VS) is expanding its audience-engagement offerings through Drinkfinger, a QR-enabled beverage carrier that connects live-event attendees with mobile games, rewards and branded content. In a recent IBN Stock2Me Podcast appearance, CEO Luis Goldner and other members of
Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements.
Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf
Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer’s and Parkinson’s diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. At U.S.